Eradication of medullary multiple myeloma by CD4+ cytotoxic human T lymphocytes directed at a single minor histocompatibility antigen

Clinical Cancer Research

Volumn 16, Issue 22, 2010, Pages 5481-5488

  Spaapen, Robbert M ^a   Groen, Richard W J ^a   Van Den Oudenalder, Kelly ^a   Guichelaar, Teun ^a   Van Elk, Maureen ^a   Aarts Riemens, Tineke ^a   Bloem, Andries C ^a   Storm, Gert ^b   Martens, Anton C ^a   Lokhorst, Henk M ^a   Mutis, Tuna ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR; TETANUS TOXOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER LOCALIZATION; CD4+ T LYMPHOCYTE; CELL CLONING; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ERADICATION THERAPY; FEMALE; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DNA-BINDING PROTEINS; HUMANS; IMMUNOTHERAPY; MICE; MINOR HISTOCOMPATIBILITY ANTIGENS; MULTIPLE MYELOMA; RECEPTORS, ANTIGEN, T-CELL;

EID: 78349240096     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1340     Document Type: Article

References (43)

1. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008;112:4371-83.
2. Bevan MJ. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004;4:595-602.
3. Bourgeois C, Veiga-Fernandes H, Joret AM, Rocha B, Tanchot C. CD8 lethargy in the absence of CD4 help. Eur J Immunol 2002;32:2199-207.
4. Nishimura T, Iwakabe K, Sekimoto M, et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999;190:617-27.
5. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003;300:337-9.
6. Surman DR, Dudley ME, Overwijk WW, Restifo NP. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol 2000;164:562-5.
7. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.
8. Kamiryo Y, Eto M, Yamada H, et al. Donor CD4 T cells are critical in allogeneic stem cell transplantation against murine solid tumor. Cancer Res 2009;69:5151-8.
9. Muranski P, Restifo NP. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol 2009;21:200-8.
10. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic t lymphocytes against major histocompatibility complex class II Negative tumors. J Exp Med 1998;187:693-702.
11. Perez-Diez A, Joncker NT, Choi K, et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007;109:5346-54.
12. Spaapen R, van den Oudenalder K, Ivanov R, Bloem A, Lokhorst H, Mutis T. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy. Clin Cancer Res 2007;13:4009-15.
13. Spaapen RM, de Kort RA, van den Oudenalder K, et al. Rapid identification of clinical relevant minor histocompatibility antigens via genome-wide zygosity-genotype correlation analysis. Clin Cancer Res 2009;15:7137-43.
14. Spaapen RM, Lokhorst HM, van den Oudenalder K, et al. Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genomewide analysis. J Exp Med 2008;205:2863-72.
15. Stumpf AN, van der Meijden ED, van Bergen CA, Willemze R, Falkenburg JH, Griffioen M. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity. Blood 2009;114:3684-92.
16. Quezada SA, Simpson TR, Peggs KS, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010;207:637-50.
17. Holloway PA, Kaldenhoven N, Kok-Schoemaker HM, et al. A class II-restricted cytotoxic T-cell clone recognizes a human minor histocompatibility antigen with a restricted tissue distribution. Br J Haematol 2005;128:73-81.
18. Rozemuller H, van der Spek E, Bogers-Boer LH, et al. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect. Haematologica 2008;93:1049-57.
19. Weijer K, Uittenbogaart CH, Voordouw A, et al. Intrathymic and extrathymic development of human plasmacytoid dendritic cell precursors in vivo. Blood 2002;99:2752-9.
20. van Rijn RS, Simonetti ER, Hagenbeek A, et al. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- γ-/- double-mutant mice. Blood 2003;102:2522-31.
21. Brown CE, Wright CL, Naranjo A, et al. Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. J Immunol Methods 2005;297:39-52.
22. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9.
23. Minnema MC, van de Donk NW, Zweegman S, et al. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplant 2008;41:779-84.
24. Terpos E, Rezvani K, Basu S, et al. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol 2005;75:376-83.
25. Zeiser R, Deschler B, Bertz H, Finke J, Engelhardt M. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant 2004;34:1057-65.
26. Zomas A, Stefanoudaki K, Fisfis M, Papadaki T, Mehta J. Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas. Bone Marrow Transplant 1998;21:1163-5.
27. Chakraverty R, Eom HS, Sachs J, et al. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood 2006;108:2106-13.
28. Corthay A, Skovseth DK, Lundin KU, et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005;22:371-83.
29. De Veerman M, Heirman C, van Meirvenne S, et al. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity. J Immunol 1999;162:144-51.
30. Symons HJ, Levy MY, Wang J, et al. The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol Blood Marrow Transplant 2008;14:499-509.
31. Xie Y, Akpinarli A, Maris C, et al. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010;207:651-67.
32. Bendle GM, Haanen JB, Schumacher TN. Preclinical development of T cell receptor gene therapy. Curr Opin Immunol 2009;21:209-14.
33. Abad JD, Wrzensinski C, Overwijk W, et al. T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother 2008;31:1-6.
34. Armstrong AC, Dermime S, Mulryan K, Stern PL, Bhattacharyya T, Hawkins RE. Adoptive transfer of anti-idiotypic T cells cure mice of disseminated B cell lymphoma. J Immunother 2004;27:227-31.
35. Boni A, Muranski P, Cassard L, et al. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood 2008;112:4746-54.
36. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005;115:1616-26.
37. Valenzuela JO, Iclozan C, Hossain MS, et al. PKCθ is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. J Clin Invest 2009;119:3774-86.
38. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-43.
39. McArdle SE, Rees RC. Tumor immunology: new perspectives. Cancer Res 2009;69:7157-9.
40. Mulligan JK, Day TA, Gillespie MB, Rosenzweig SA, Young MR. Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions. Hum Immunol 2009;70:375-82.
41. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005;54:307-14.
42. Gajewski TF, Meng Y, Blank C, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006;213:131-45.
43. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001;2:293-9.